Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. CAR20-19 and CAR22 cotransduction and screening assay design.
  • Fig. S2. Combinations of CAR20-19 and CAR22 were screened for cytolytic activity against Raji cells.
  • Fig. S3. CAR20-19 and CAR22 single CAR controls were screened for cytolytic and proliferative ability.
  • Fig. S4. Costimulatory domain placement affects the killing potency of the four best CAR20-19 and CAR22 pairs.
  • Fig. S5. Mono- and tandem-CARs are robustly expressed in human primary T cells.
  • Fig. S6. DuoCAR D1, D2, D3, and D4 display an early differentiated memory phenotype and low exhaustion.
  • Fig. S7. DuoCAR-T cells eradicate Raji NHL and NALM-6 ALL tumors in NSG xenograft models.
  • Fig. S8. Characterization of A431-luciferase cell line clones stably expressing CD19, CD20, or CD22 B cell antigens.
  • Fig. S9. Characterization of Raji-luciferase cell line clones with deleted expression of B cell antigens CD19, CD20, or CD22.
  • Fig. S10. Elimination of tumors by CAR M19b in the antigen-heterogeneous Raji tumor model.
  • Fig. S11. Identification of signaling pathways activated by DuoCAR D2, its components T3 and M22, and the tandem CAR-T1.
  • Fig. S12. Identification of signaling pathways activated by duoCAR D3, its components T3 and M22s, and the tandem CAR-T1.
  • Fig. S13. Identification of signaling pathways activated by duoCAR D4, its components T4 and M22s, and the tandem CAR-T1.

[Download PDF]

Other Supplementary Material for this manuscript includes the following: